Raúl Ibarra-Salce

Dr. Raúl Ibarra-Salce

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Manuel Ramón García-SáenzManuel Ramón García-Sáenz
Manuel Ramón García-Sáenz
RIRaúl Ibarra-Salce
Raúl Ibarra-Salce
FPFrancisco Javier Pozos-Varela
Francisco Javier Pozos-Varela
TMTania Sofia Mena-Ureta
Tania Sofia Mena-Ureta
SFSusana Flores
Susana Flores
Aldo Ferreira-HermosilloAldo Ferreira-Hermosillo
Aldo Ferreira-Hermosillo
Progestin is a term used to describe a synthetic progestogen. The activity and potency of synthetic progestins are mostly evaluated via parameters associated with their endometrial effects, which are related to their interactions with progesterone, estrogen, androgen, glucocorticoid, and mineralocorticoid receptors. The chemical structure of progestins is the key to understanding their interactions with these receptors and predicting the other effects associated with these drugs. Due to their endometrial effect, progestins are used for different gynecological conditions, such as endometriosis, contraception, hormonal replacement therapy, and artificial reproduction techniques. This review is focused on improving our knowledge of progestins (from their history and biochemical effects related to their chemical structures to clinical applications in gynecological conditions) in order to improve clinical practice.

18 September 2020 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
MMMoises Mercado
Moises Mercado
CACoralys Abreu
Coralys Abreu
AVAlma Vergara-López
Alma Vergara-López
BGBaldomero José Gregorio González-Virla
Baldomero José Gregorio González-Virla
AEAna-Laura Espinosa-De-Los-Monteros
Ana-Laura Espinosa-De-Los-Monteros
JTJuan O. Talavera
Juan O. Talavera
Context: Acromegaly registries constitute a valuable source of therapeutic outcome information in real-life. Objective: The objective of this work is to analyze surgical and pharmacological outcomes in the Mexican Acromegaly Registry (MAR). Design and Methods: Data were extracted from the MAR informatic platform. Surgical remission was defined by a postoperative postglucose (GH) of less than 1 ng/mL and an insulin-like growth factor 1 (IGF-1) of less than 1.2 × upper limit of normal (ULN). Pharmacological remission was defined by a basal GH of less than 1 ng/mL and an IGF-1 of less than 1.2 × ULN. Results: A total of 650 surgical outcomes were analyzed (94.6% transsphenoidal). Surgical remission was achieved in 40.15%, whereas 44.15% remained biochemically active. Persistently active disease after surgery was significantly associated with harboring an invasive macroadenoma, a basal GH of greater than 10 ng/mL, and/or an IGF-1 of greater than 2 × ULN at diagnosis on bivariate and multivariate analysis. The outcome of monotherapy with first-generation somatostatin analogs (SSAs) was evaluated in 267 patients (adjunctive in 65%), of whom 28.4% achieved remission. Persistently active disease was significantly associated with harboring an invasive macroadenoma as well as with pretreatment basal GH and IGF-1 levels of greater than 10 ng/mL and greater than 2 × ULN, respectively, on bivariate and multivariate analysis. Combined therapy with SSA and cabergoline was analyzed in 100 patients, of whom 19% achieved remission and 44% remained active; in this subset of patients, only a pretreatment IGF-1 of greater than 2 × ULN was significantly associated with persistent disease activity. Conclusion: Surgical and pharmacological outcomes in acromegaly are highly dependent on tumor size/invasiveness as well as on the degree of hypersomatotropinemia.

7 January 2023 in Endocrine Practice
Verified
Journal Article
Closed access
RIRaúl Ibarra-Salce
Raúl Ibarra-Salce
FPFrancisco Javier Pozos-Varela
Francisco Javier Pozos-Varela
NMNestor Martinez-Zavala
Nestor Martinez-Zavala
CLCesar Ernesto Lam-Chung
Cesar Ernesto Lam-Chung
TMTania Sofia Mena-Ureta
Tania Sofia Mena-Ureta
PAPaloma Almeda-Valdés
Paloma Almeda-Valdés

16 July 2026 in Metabolites
Verified
Journal Article
Open access
PDF file
RIRaúl Ibarra-Salce
Raúl Ibarra-Salce
Jose Luis Eduardo Doval CaballeroJose Luis Eduardo Doval Caballero
Jose Luis Eduardo Doval Caballero
DUDaniel Uribe-Cortés
Daniel Uribe-Cortés
GEGenesis Dinora Eugenio-Ponce
Genesis Dinora Eugenio-Ponce
MSMariela Ibarra Salce
Mariela Ibarra Salce
Manuel Ramón García-SáenzManuel Ramón García-Sáenz
Manuel Ramón García-Sáenz
Background/Objectives: Type 2 diabetes is increasingly recognized as a systemic disorder driven not only by chronic hyperglycemia and insulin resistance, but also by dysregulated interorgan communication. Extracellular vesicles (EVs), including exosomes and microvesicles, have emerged as biologically active carriers of proteins, lipids, and microRNAs capable of modulating gene expression in recipient cells. This narrative review integrates clinical, experimental, and translational evidence on EV-associated microRNAs as candidate biomarkers and potential mediators of diabetic complications, with emphasis on diabetic neuropathy, diabetic kidney disease, diabetic retinopathy, and metabolic dysfunction-associated steatotic liver disease (MASLD). Methods: This review was aligned with the SANRA framework and focused on biological plausibility, evidence from tissue and biofluids, biomarker potential, therapeutic implications, and barriers to clinical translation. Studies were additionally interpreted according to biological matrix, EV-carrier specificity, analytical platform, study design, and level of functional validation. Results: Across complications, EV-associated microRNAs appear to participate in shared pathogenic processes, including oxidative stress, inflammation, endothelial dysfunction, fibrosis, angiogenesis, neurodegeneration, and metabolic memory. In diabetic neuropathy, microRNAs such as miR-146a, miR-155, miR-21-5p, and miR-148a-3p have been linked to neuroinflammation, Schwann-cell dysfunction, axonal injury, and neuropathic pain. In diabetic kidney disease, miR-21, miR-29, miR-30, and miR-126 are implicated in podocyte injury, tubulointerstitial fibrosis, albuminuria, and microvascular dysfunction. In diabetic retinopathy, microRNAs including miR-146a, miR-155, miR-21, miR-126, and miR-200b contribute to neurovascular injury, inflammation, barrier disruption, and angiogenesis. In MASLD associated with diabetes, hepatocyte-derived EVs carrying microRNAs such as miR-1 and miR-126a-3p may link hepatic lipotoxicity to endothelial inflammatory and β-cell dysfunction. Conclusions: Although EV-associated microRNAs offer promising opportunities for biomarker discovery, risk stratification, and targeted therapies, clinical translation remains limited by heterogeneity in EV isolation, microRNA quantification, biological matrices, and outcome definitions. Distinguishing EV-associated miRNAs from total circulating extracellular miRNAs remains essential for biological interpretation. Standardized, longitudinal, and externally validated studies are required before these signals can be implemented as actionable tools in precision diabetes care.

22 December 2025 in Revista Mexicana de Endocrinología, Metabolismo y Nutrición
Verified
Journal Article
Open access
PDF file
RIRaúl Ibarra-Salce
Raúl Ibarra-Salce
MGManuel R. García-Sáenz
Manuel R. García-Sáenz
ATAndrea P. Tenorio-Rojo
Andrea P. Tenorio-Rojo
MSMario A. Santana-Mata
Mario A. Santana-Mata
SFSusana P. Flores-Villagomez
Susana P. Flores-Villagomez
ACAna C. Cepeda-Nieto
Ana C. Cepeda-Nieto
Antecedentes: El aldosteronismo primario (AP) es la causa más frecuente de hipertensión secundaria y es constantemente infradiagnosticado. La prueba de supresión valsartán-dexametasona- captopril (VDCST) es una prueba que posee buen rendimiento diagnóstico. Objetivo: Validar en población mexicana la VDCST para el diagnóstico de AP. Método: Estudio prospectivo de prueba diagnóstica. Comparación entre la VDCST y la relación aldosterona-renina (PAC/PRC) en combinación con aldosterona urinaria de 24 horas con carga oral de sodio. Resultados: Tres de 27 pacientes fueron diagnosticados. El área bajo la curva para la aldosterona post VDCST fue de 0.986 (p = 0.007, IC 95%: 0.945-1.00), y para el PAC/PRC post-VDCST de 0.972 (p = 0.009, IC 95%: 0.911-1.000). Aldosterona post-VDCST y PAC/PRC post- VDCST alcanzó sensibilidad del 100% y especificidad del 88% con valores de corte de 5.1 ng/dL y 0.88 ng/dL/mUI/L, respectivamente. Conclusiones: PAC/PRC puede infradiagnosticar el AP. La VDCST cuenta con buen rendimiento diagnóstico de AP. La renina estimulada puede diferenciar pacientes con AP que se muestran negativos con otras pruebas.